Long-term effects of weight-reducing drugs in people with hypertension

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554 · see citing works

The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants

Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,577 · see citing works

Cochrane Handbook for Systematic Reviews of Interventions

(2019) · doi:10.1002/9781119536604 · Cited by 14,828 · see citing works

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681 · see citing works

2018 ESC/ESH Guidelines for the management of arterial hypertension

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286 · see citing works

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · see citing works

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391 · see citing works

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347 · see citing works

Oral health of individuals aged 3-80 years in Jönköping, Sweden during 40 years (1973-2013). II. Review of clinical and radiographic findings.

Norderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584 · see citing works

European Guidelines for Obesity Management in Adults

Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432 · see citing works

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · see citing works

A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial

Fuller, N. R., Colagiuri, S., SCHOFIELD, D. J., Olson, A. D., Shrestha, R. N., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,125 · see citing works

XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study

Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915 · see citing works

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,500 · see citing works

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · see citing works

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · see citing works

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.

Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237 · see citing works

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients

Pi-Sunyer, X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & for the RIO-North America Study Group (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,209 · see citing works

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064 · see citing works

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036 · see citing works

Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial

Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · see citing works

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · see citing works

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · see citing works

Long-term Drug Treatment for Obesity: A Systematic and Clinical Review

Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876 · see citing works

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · see citing works

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M., & Gaal, L. F. V. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03491-7 · Cited by 817 · see citing works

Drug treatments for obesity: orlistat, sibutramine, and rimonabant

Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · see citing works

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

Scheen, A. J., Finer, N., Hollander, P. A., Jensen, M. D., & Gaal, L. F. V. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69571-8 · Cited by 729 · see citing works

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720 · see citing works

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study

Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716 · see citing works

Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP)

Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711 · see citing works

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

on behalf of the SCALE study group, Blackman, A., Foster, G. D., Zammit, G., Rosenberg, R., Aronne, L., Wadden, T., Claudius, B., Jensen, C. B., & Mignot, E. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.52 · Cited by 583 · see citing works

Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children

Nerenberg, K. A., Zarnke, K. B., Leung, A. A., Dasgupta, K., Butalia, S., McBrien, K., Harris, K. C., Nakhla, M., Cloutier, L., Gelfer, M., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.022 · Cited by 573 · see citing works

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

Fidler, M. C., Sanchez, M., Raether, B., Weissman, N. J., Smith, S. R., Shanahan, W. R., & Anderson, C. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1256 · Cited by 561 · see citing works

Weight loss with naltrexone sr/bupropion sr combination therapy as an adjunct to behavior modification: the COR-BMOD trial

Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558 · see citing works

Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

O'Neil, P. M., Smith, S. R., Weissman, N. J., Fidler, M. C., Sanchez, M., Zhang, J., Raether, B., Anderson, C. M., & Shanahan, W. R. (2012) · Obesity · doi:10.1038/oby.2012.66 · Cited by 528 · see citing works

Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors

Hróbjartsson, A., Thomsen, A. S. S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I., Ravaud, P., & Brorson, S. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.120744 · Cited by 527 · see citing works

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes

Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501 · see citing works

Weight Loss, Weight Maintenance, and Improved Cardiovascular Risk Factors after 2 Years Treatment with Orlistat for Obesity

Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476 · see citing works

Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease

Nissen, S. E., Nicholls, S. J., Wolski, K., Rodés‐Cabau, J., Cannon, C. P., Deanfield, J. E., Després, J., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S. R., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1547 · Cited by 406 · see citing works

Sibutramine Produces Dose‐Related Weight Loss

Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., et al. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00701.x · Cited by 383 · see citing works

Orlistat in the long-term treatment of obesity in primary care settings.

Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367 · see citing works

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., & Leutenegger, É. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00411-2 · Cited by 343 · see citing works

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

Finer, N., James, W. P. T., Kopelman, P. G., Lean, M., & Williams, G. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801128 · Cited by 324 · see citing works

Clinical Efficacy of Orlistat Therapy in Overweight and Obese Patients With Insulin-Treated Type 2 Diabetes

Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314 · see citing works

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286 · see citing works

Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults

Aronne, L. J., Wadden, T. A., Peterson, C., Winslow, D., Odeh, S., & Gadde, K. M. (2013) · Obesity · doi:10.1002/oby.20584 · Cited by 274 · see citing works

Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool: Baseline imbalance assessment and risk of bias

Corbett, M. S., Higgins, J. P. T., & Woolacott, N. F. (2014) · Research Synthesis Methods · doi:10.1002/jrsm.1090 · Cited by 273 · see citing works

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial

Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273 · see citing works

Long-term Weight Loss With Sibutramine

Wirth, A. G., & Krause, J. (2001) · JAMA · doi:10.1001/jama.286.11.1331 · Cited by 267 · see citing works

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

Topol, E. J., Bousser, M.-G., Fox, K. A., Creager, M. A., Despres, J.-P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60935-x · Cited by 266 · see citing works

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808721 · Cited by 265 · see citing works

Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension

McMahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F. K., & Mooradian, A. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2185 · Cited by 246 · see citing works

Glucagon-like peptide analogues for type 2 diabetes mellitus

Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · see citing works

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00081.x · Cited by 244 · see citing works

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 244 · see citing works

Effects of Weight Loss in Overweight/Obese Individuals and Long-Term Hypertension Outcomes: A Systematic Review

Aucott, L., Poobalan, A., Smith, W. C. S., Avenell, A., Jung, R., & Broom, J. (2005) · Hypertension · doi:10.1161/01.hyp.0000165680.59733.d4 · Cited by 241 · see citing works

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

Caixàs, A., Albert, L., Capel, I., & Rigla, M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s55587 · Cited by 236 · see citing works

Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release

Garvey, W. T., Ryan, D. H., Henry, R., Bohannon, N. J. V., Toplak, H., Schwiers, M., Troupin, B., & Day, W. W. (2014) · Diabetes Care · doi:10.2337/dc13-1518 · Cited by 215 · see citing works

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study

Lindgärde, F. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00720.x · Cited by 203 · see citing works

Effect of Rimonabant on the High-Triglyceride/ Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat

Després, J., Ross, R., Boka, G., Alméras, N., & Lemieux, I. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.176362 · Cited by 198 · see citing works

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo

Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1350 · Cited by 179 · see citing works

A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin

McNulty, S., Ur, E., & Williams, G. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.125 · Cited by 167 · see citing works

A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults

Winslow, D. H., Bowden, C. H., DiDonato, K. P., & McCullough, P. A. (2012) · Sleep · doi:10.5665/sleep.2204 · Cited by 163 · see citing works

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rössner, S., Hanotin, C., & Ziegler, O. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn076 · Cited by 156 · see citing works

Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients Systematic Review and Meta-analysis

Horvath, K. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.571 · Cited by 141 · see citing works

Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

Russell-Jones, D. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.018 · Cited by 137 · see citing works

Efficacy and safety of lorcaserin in obese adults: a meta‐analysis of 1‐year randomized controlled trials ( RCTs ) and narrative review on short‐term RCTs

Chan, E. W., He, Y., Chui, C. S. L., Wong, A. Y. S., Lau, W. C. Y., & Wong, I. C. K. (2013) · Obesity Reviews · doi:10.1111/obr.12015 · Cited by 134 · see citing works

Long-term effects of weight-reducing diets in hypertensive patients

Siebenhofer, A., Jeitler, K., Berghold, A., Waltering, A., Hemkens, L. G., Semlitsch, T., Pachler, C., Strametz, R., & Horvath, K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008274.pub2 · Cited by 121 · see citing works

A one-year trial to assess the value of orlistat in the management of obesity.

James, W. P. T., Avenell, A., Broom, J. I., & Whitehead, J. (1997) · PubMed · Cited by 118 · see citing works

Treatment with orlistat reduces cardiovascular risk in obese patients

Zavoral, J. H. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816121-00024 · Cited by 116 · see citing works

Long-term effects of weight-reducing drugs in people with hypertension

Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Posch, N. A. S., Meschik, J., & Semlitsch, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub4 · Cited by 116 · see citing works

Obesity-Related Hypertension?

Kotchen, T. A. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.120915 · Cited by 116 · see citing works

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X

Reaven, G. M., Segal, K. R., Hauptman, J. B., Boldrin, M. N., & Lucas, C. P. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01521-6 · Cited by 110 · see citing works

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

McMahon, F. G., Weinstein, S. P., Rowe, E., Ernst, K. R., Johnson, F., & Fujioka, K. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001298 · Cited by 108 · see citing works

A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity

Fanghänel, G., Cortinas, L., Sánchez‐Reyes, L., & Berber, A. C. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801098 · Cited by 108 · see citing works

Effect of Sibutramine on Weight Loss and Blood Pressure: A Meta‐analysis of Controlled Trials

Kim, S. H., Lee, Y., Jee, S. H., & Nam, C. M. (2003) · Obesity Research · doi:10.1038/oby.2003.152 · Cited by 106 · see citing works

RANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY

Broom, J. I., Wilding, J. P. H., Stott, P., Myers, N., & UK Multimorhidity Study Group (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11307.x · Cited by 103 · see citing works

Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

Dujovne, C. A., Zavoral, J. H., Rowe, E., & Mendel, C. M. (2001) · American Heart Journal · doi:10.1067/mhj.2001.117510 · Cited by 100 · see citing works

Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome

Heinonen, M. V., Laaksonen, D. E., Karhu, T., Karhunen, L. J., Laitinen, T. P., Kainulainen, S., Rissanen, A., NISKANEN, L. K., & Herzig, K. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.12.008 · Cited by 97 · see citing works

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

Bakris, G. L., Calhoun, D. A., Egan, B. M., Hellmann, C. P., Dolker, M., & Kingma, I. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00026 · Cited by 96 · see citing works

Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women

Tiikkainen, M., Bergholm, R., Rissanen, A., Aro, A., Salminen, I., Tamminen, M., Teramo, K., & Yki‐Järvinen, H. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.1.22 · Cited by 88 · see citing works

The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy

Fujioka, K., Plodkowski, R. A., O'Neil, P. M., Gilder, K. M., Walsh, B., & Greenway, F. L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.67 · Cited by 88 · see citing works

Absence of Cardiac Valve Dysfunction in Obese Patients Treated with Sibutramine

Bach, D. S., Rissanen, A., Mendel, C. M., Shepherd, G. M., Weinstein, S. P., Kelly, F., Seaton, T. B., Putel, B., Pekkarinen, T., & Armstrong, W. F. (1999) · Obesity Research · doi:10.1002/j.1550-8528.1999.tb00419.x · Cited by 85 · see citing works

Effect of orlistat on cardiovascular disease risk in obese adults

Swinburn, B. A., Carey, D., Hills, A. P., Hooper, M., Marks, S., Proietto, J., Strauss, B. J., Sullivan, D., Welborn, T. A., & Caterson, I. D. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00467.x · Cited by 81 · see citing works

Weight Loss Medications in the Treatment of Obesity and Hypertension

Cohen, J. B., & Gadde, K. M. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0915-1 · Cited by 80 · see citing works

Weight Reduction by Sibutramine in Obese Subjects in Primary Care Medicine: The S. A. T. Study

Hauner, H., Meier, M., Wendland, G., Kurscheid, T., & Lauterbach, K. W. (2004) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-817934 · Cited by 72 · see citing works

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

Zannad, F., Gille, B., Grentzinger, A., Bruntz, J.-F., Hammadi, M., Boivin, J.-M., Hanotin, C., Igau, B., & Drouin, P. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124403 · Cited by 71 · see citing works

Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

Halpern, A., Mancini, M. C., Suplicy, H., Zanella, M. T., Repetto, G., Gross, J. L., Jadzinsky, M. N., Barranco, J. G., Aschner, P. J., Ramirez, L., et al. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00262.x · Cited by 71 · see citing works

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

Derosa, G., Mugellini, A., Ciccarelli, L., & Fogari, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80070-x · Cited by 71 · see citing works

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

von Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.004 · Cited by 69 · see citing works

Evaluation of efficacy and safety of orlistat in obese patients

Jain, S., Ramanand, S., Ramanand, J. B., Akat, P. B., Patwardhan, M., & Joshi, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.81938 · Cited by 69 · see citing works

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

Derosa, G., Cicero, A. F. G., Murdolo, G., Piccinni, M. N., Fogari, E., Bertone, G., Ciccarelli, L., & Fogari, R. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00372.x · Cited by 67 · see citing works

Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial

O’Leary, D. H., Reuwer, A. Q., Nissen, S. E., Després, J., Deanfield, J. E., Brown, M. W., Zhou, R., Zabbatino, S., Job, B., Kastelein, J. J. P., et al. (2011) · Heart · doi:10.1136/hrt.2011.223446 · Cited by 61 · see citing works

Principles for Enhanced Recruitment of Subjects in a Large Clinical Trial

Torgerson, J., Arlinger, K., Käppi, M., & Sjöström, L. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00165-9 · Cited by 61 · see citing works

Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

Kaukua, J., Pekkarinen, T., & Rissanen, A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802591 · Cited by 60 · see citing works

Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

Samuelsson, L., Gottsäter, A., & Lindgärde, F. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00264.x · Cited by 54 · see citing works

Long-term effects of weight-reducing drugs in hypertensive patients

Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub3 · Cited by 51 · see citing works

New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

Scheen, A. J., & Ernest, P. (2002) · PubMed · Cited by 50 · see citing works

Endocannabinoid Blockade for Improving Glycemic Control and Lipids in Patients with Type 2 Diabetes Mellitus

Hollander, P. A. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.11.014 · Cited by 49 · see citing works

Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice

Gadde, K. M., & Raj, Y. P. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0859-2 · Cited by 46 · see citing works

Effects of orlistat on obesity‐related diseases – a six‐month randomized trial

Guy-grand, B., Drouin, P., Eschwège, É., Gin, H., Joubert, J., & Valensi, P. E. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00359.x · Cited by 44 · see citing works

Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase–9 in obese subjects

Madsen, E. L., Bruun, J. M., Skogstrand, K., Hougaard, D. M., Christiansen, T., & Richelsen, B. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.031 · Cited by 43 · see citing works

Liraglutide: A Review of Its Use in the Management of Obesity

Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0408-8 · Cited by 43 · see citing works

Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis

le Roux, C. W., Aroda, V. R., Uddén, J., Cancino, A., Christensen, R. H. B., & Pi-Sunyer, X. (2017) · Obesity Facts · doi:10.1159/000478099 · Cited by 41 · see citing works

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management

Kolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., & Bjorner, J. B. (2016) · Clinical Obesity · doi:10.1111/cob.12146 · Cited by 40 · see citing works

Effect of Orlistat on Eating Behavior Among Participants in a 3‐year Weight Maintenance Trial

Svendsen, M., Rissanen, A., Richelsen, B., Rössner, S., Hansson, F., & Tonstad, S. (2008) · Obesity · doi:10.1038/oby.2007.82 · Cited by 38 · see citing works

Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over

Fanghänel, G., Cortinas, L., Sánchez‐Reyes, L., & Berber, A. C. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801592 · Cited by 38 · see citing works

The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update

Christou, G. A., & Kiortsis, D. N. (2015) · HORMONES · doi:10.14310/horm.2002.1600 · Cited by 37 · see citing works

Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations

Erdmann, J., Lippl, F., Klose, G., & SCHUSDZIARRA, V. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01966.x · Cited by 37 · see citing works

Safety and tolerability review of lorcaserin in clinical trials

Greenway, F. L., Shanahan, W. R., Fain, R., Ma, T., & Rubino, D. (2016) · Clinical Obesity · doi:10.1111/cob.12159 · Cited by 36 · see citing works

Cost-Effectiveness Analysis of Qsymia for Weight Loss

Finkelstein, E. A., Kruger, E., & Karnawat, S. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0182-6 · Cited by 34 · see citing works

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double‐blind, randomized, placebo‐controlled trial

Tambascia, M. A., Geloneze, B., Repetto, E. M., Geloneze, S. R., Picolo, M., & Magro, D. O. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2003.00285.x · Cited by 34 · see citing works

Long-term effects of weight-reducing drugs in hypertensive patients

Siebenhofer, A., Horvath, K., Jeitler, K., Berghold, A., Stich, A. K., Matyas, E., Pignitter, N., & Siering, U. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub2 · Cited by 32 · see citing works

Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2

Davidson, M. H., Tonstad, S., Oparil, S., Schwiers, M., Day, W. W., & Bowden, C. H. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.12.038 · Cited by 31 · see citing works

Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

Hung, Y. ‐., Chen, Y., Pei, D., Kuo, S. ‐., Hsieh, C. ‐., Wu, L. ‐., He, C., Lee, C.-H., Fan, S. C., & Sheu, W. H. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01569.x · Cited by 31 · see citing works

Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease

Seimon, R. V., Espinoza, D., Ivers, L., Gebski, V., Finer, N., Legler, U. F., Sharma, A. M., James, W. P. T., Coutinho, W. F., & Caterson, I. D. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.2 · Cited by 30 · see citing works

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion

Halseth, A. E., Shan, K., Gilder, K. M., Malone, M., Acevedo, L. M., & Fujioka, K. (2018) · Obesity Science & Practice · doi:10.1002/osp4.156 · Cited by 30 · see citing works

Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients

Faria, A. N., Filho, F. F. R., Kohlmann, N. E. B., Ferreira, S. R. G., & Zanella, M. T. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00465.x · Cited by 29 · see citing works

Effects of Sibutramine on the Treatment of Obesity in Patients with Arterial Hypertension

Faria, A. N., Filho, F. F. R., Lerario, D. D. G., Kohlmann, N. E. B., Ferreira, S. R. G., & Zanella, M. T. (2002) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2002000200006 · Cited by 25 · see citing works

A Randomized Trial of Lorcaserin and Lifestyle Counseling for Maintaining Weight Loss Achieved with a Low‐Calorie Diet

Tronieri, J. S., Wadden, T. A., Berkowitz, R. I., Chao, A. M., Pearl, R. L., Alamuddin, N., Leonard, S. M., Carvajal, R., Bakizada, Z. M., Pinkasavage, E., et al. (2017) · Obesity · doi:10.1002/oby.22081 · Cited by 25 · see citing works

Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension

Fanghänel, G., Cortinas, L., Sánchez‐Reyes, L., Gómez‐Santos, R., Campos-Franco, E., & Berber, A. C. (2003) · Advances in Therapy · doi:10.1007/bf02850257 · Cited by 23 · see citing works

Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

Maggioni, A. P., Caterson, I. D., Coutinho, W. F., Finer, N., Gaal, L. V., Sharma, A. M., Torp-Pedersen, C. T., Bacher, P. H., Shepherd, G. M., Sun, R., et al. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31818713d6 · Cited by 22 · see citing works

Untitled work

Petrie (2016) · doi:10.1097/hjh.0000000000000890 · Cited by 20 · see citing works

Lorcaserin for weight management

Taylor, J., Dietrich, E. A., & Powell, J. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s36276 · Cited by 19 · see citing works

Drugs to treat obesity: do they work?

Kim, S. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133388 · Cited by 18 · see citing works

A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.

de Castro, J. J., Dias, T., Chambel, P., Carvalheiro, M. C., Correia, L. G., Guerreiro, L., Marques, O., Medina, J. L., Nobre, E. L., Silva‐Nunes, J., et al. (2009) · PubMed · Cited by 17 · see citing works

Influence of Sibutramine on Energy Expenditure in African American Women

Starling, R. D., Liu, X., & Sullivan, D. H. (2001) · Obesity Research · doi:10.1038/oby.2001.29 · Cited by 17 · see citing works

Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study

Halpern, A., Leite, C. C., Herszkowicz, N., Barbato, A. J. G., & da Costa, A. P. H. (2002) · Revista do Hospital das Clínicas · doi:10.1590/s0041-87812002000300003 · Cited by 17 · see citing works

Does Rimonabant Independently Affect Free Fatty Acid and Glucose Metabolism?

Triay, J., Mundi, M. S., Klein, S., Toledo, F. G. S., Smith, S. R., Abu-Lebdeh, H. S., & Jensen, M. D. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2486 · Cited by 16 · see citing works

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

Derosa, G., D’Angelo, A., SALVADEO, S. A. T., Ferrari, I., Gravina, A., Fogari, E., Maffioli, P., & Cicero, A. F. G. (2008) · Metabolism · doi:10.1016/j.metabol.2008.06.010 · Cited by 16 · see citing works

Sufficient Weight Reduction Decreases Cardiovascular Complications in Diabetic Patients with the Metabolic Syndrome

Cocco, G., Pandolfi, S., & Rousson, V. (2005) · Heart Drug · doi:10.1159/000083662 · Cited by 14 · see citing works

Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients

Derosa, G., Maffioli, P., Ferrari, I., Palumbo, I., Randazzo, S., D’Angelo, A., & Cicero, A. F. G. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01217.x · Cited by 13 · see citing works

Effects of One Year Treatment of Sibutramine on Insulin Resistance Parameters in Type 2 Diabetic Patients

Derosa, G., Maffioli, P., Ferrari, I., Palumbo, I., Randazzo, S., D’Angelo, A., & Cicero, A. F. G. (2010) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3388p · Cited by 13 · see citing works

S28 Liraglutide 3.0 Mg Reduces Severity Of Obstructive Sleep Apnoea And Body Weight In Obese Individuals With Moderate Or Severe Disease: Scale Sleep Apnoea Trial

Collier, A., Blackman, A., Foster, G. D., Zammit, G. K., Rosenberg, R. P., Wadden, T. A., Aronne, L. J., Claudius, B., Jensen, T. B., & Mignot, E. J.-M. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206260.34 · Cited by 13 · see citing works

Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.

Pathan, M. F., Latif, Z., Nazneen, N. E., & Mili, S. (2004) · PubMed · Cited by 9 · see citing works

Liraglutide 3.0 mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Overweight/Obesity: The SCALE Obesity and Prediabetes Randomised Trial

Lau, D. C. W., Krempf, M., Astrup, A. V., le Roux, C. W., Fujioka, K., Greenway, F. L., Halpern, A., Ortíz, R. V., Wilding, J. P. H., Boras, D., et al. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.01.183 · Cited by 8 · see citing works

EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL

James, P., Caterson, I. D., Coutinho, W. F., Finer, N., Gaal, L. V., Maggioni, A. P., & Sharma, A. M. (2010) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(10)61327-7 · Cited by 8 · see citing works

Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity

Levinson, P. D. (2001) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.6.2.54 · Cited by 7 · see citing works

Liraglutide, GLP-1 receptor agonist, for chronic weight loss

Moore, K. G., Shealy, K. M., & Clements, J. N. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1220295 · Cited by 7 · see citing works

Efficacy and safety of liraglutide 3.0mg for weight management in overweight and obese adults: The SCALE Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial

Proietto, J., le Roux, C. W., Pi‐Sunyer, X., Astrup, A. V., Fujioka, K., Greenway, F. L., Halpern, A., Lau, D. C. W., Ortíz, R. V., Philips, A., et al. (2014) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2014.10.210 · Cited by 7 · see citing works

Effects of Liraglutide 3.0 mg and 1.8 mg on Body Weight and Cardiometabolic Risk Factors in Adults with Overweight or Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled, 56-Week Trial

Pedersen, S. D., DeFronzo, R. A., Bergenstal, R. M., Bode, B. W., Kushner, R. F., Lewin, A. J., Noctor, M., Boras, D., & Davies, M. J. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.01.141 · Cited by 6 · see citing works

[Sibutramine--antidepressive agent tested against obesity].

Rössner, S. (2001) · PubMed · Cited by 6 · see citing works

Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes

Kamil, S., Finer, N., James, W. P. T., Caterson, I. D., Andersson, C., & Torp-Pedersen, C. T. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw029 · Cited by 6 · see citing works

Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population

Lu, C., Chang, C., Yang, Y., Lin, W., & Huang, K. (2018) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2018.07.007 · Cited by 6 · see citing works

WEIGHT LOSS, BLOOD PRESSURE, PULSE AND CIRCADIAN PATTERNS WITH NALTREXONE SUSTAINED-RELEASE/BUPROPION SUSTAINED-RELEASE COMBINATION THERAPY FOR OBESITY

Plutzky, J., CHILTON, R. J., Still, C. D., Burns, C. M., Kim, D. S., & Dunayevich, E. (2011) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(11)60517-2 · Cited by 6 · see citing works

WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE

Davidson, M. H., Bowden, C. H., & Day, W. W. (2011) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(11)60545-7 · Cited by 6 · see citing works

Long-term effects of weight-reducing drugs in hypertensive patients

Siebenhofer, A., Horvath, K., Jeitler, K., Berghold, A., Stich, A. K., Matyas, E., Pignitter, N., & Siering, U. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654 · Cited by 6 · see citing works

Liraglutide 3.0mg improves body weight and cardiometabolic risk factors in overweight or obese adults without diabetes: The SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 56-week trial

Wittert, G., le Roux, C. W., Astrup, A. V., Fujioka, K., Greenway, F. L., Halpern, A., Lau, D. C. W., Ortíz, R. V., Wilding, J. P. H., Furber, S., et al. (2014) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2014.10.211 · Cited by 5 · see citing works

Liraglutide 3.0 mg Reduces Severity of Obstructive Sleep Apnea and Body Weight in Individuals with Obesity and Moderate or Severe Disease: SCALE Sleep Apnoea Trial

Blackman, A., Foster, G. D., Zammit, G. K., Rosenberg, R. P., Wadden, T. A., Aronne, L. J., Donsmark, M., & Boras, D. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.01.139 · Cited by 5 · see citing works

Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria

Blackman, A., Foster, G. D., Zammit, G. K., Rosenberg, R. P., Aronne, L. J., Wadden, T. A., Claudius, B., Jensen, C., & Mignot, E. J.-M. (2015) · Sleep Medicine · doi:10.1016/j.sleep.2015.02.058 · Cited by 5 · see citing works

Comparison of efficacy and safety of rimonabant with orlistat in obese and overweight patients

Suyog, D. J., Patwardhan, M., & Ramteke, K. (2011) · International Journal of Pharma and Bio Sciences · Cited by 4 · see citing works

Trial of Lorcaserin for Weight Management

Jia, J., Xiong, L., & Chen, S. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1009975 · Cited by 3 · see citing works

Effect of Weight Loss (WL) on Concomitant Medication Costs in Obese/Overweight individuals with Metabolic Syndrome (METS) receiving Phentermine/Topiramate extended-release (PHEN/TPM ER)

Kahan, S. I., & Karnawat, S. (2015) · Value in Health · doi:10.1016/j.jval.2015.03.1730 · Cited by 3 · see citing works

Abstract P027: Obesity Treatment-Induced Weight Loss Improves Resting Blood Pressure and Reduces Progression from Prehypertension to Hypertension in Overweight/Obese Adults

Gupta, A., Church, T. S., & Day, W. W. (2013) · Circulation · doi:10.1161/circ.127.suppl_12.ap027 · Cited by 3 · see citing works

Efficacy and safety of liraglutide 3.0 mg in adult overweight and obese weight loss responders without diabetes: results of the randomised, double-blind, placebo-controlled 56-week SCALE Obesity and Prediabetes trial

O’Neil, P. J., Fujioka, K., Ortiz, R. V., Claudius, B., Jensen, C., Astrup, A. V., Kienhöfer, J., & Hamann, A. (2015) · Diabetologie und Stoffwechsel · doi:10.1055/s-0035-1556574 · Cited by 2 · see citing works

[Efficacy and safety of a short-time orlistat treatment in obese subjects].

(2005) · PubMed · Cited by 2 · see citing works

AB0847 Impact of Body Weight Loss on the Clinical Manifestations of Knee Osteoarthritis and Metabolic Syndrome Parameters in Female Patients with Obesity Taking Orlistat

Strebkova, E. A., Solovyova, I. V., Sharapova, E. P., Mkrtumyan, A. M., Alekseeva, L. I., & Nasonov, E. L. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-eular.2857 · Cited by 2 · see citing works

IMPROVEMENT IN SF-36-DERIVED HEALTH UTILITY SCORE WITH LIRAGLUTIDE 3.0 MG VERSUS PLACEBO OVER 3 YEARS IN PREDIABETES

Kolotkin, R. L., Smolarz, B. G., Meincke, H. H., & Bjorner, J. B. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.996 · Cited by 1 · see citing works

Cost-Utility Analysis of Lorcaserin In The Treatment of Obesity

Sharif, Z., Peikanpour, M., Rangchian, M., & Moghadam, M. J. F. (2016) · Value in Health · doi:10.1016/j.jval.2016.09.1405 · Cited by 1 · see citing works

Effect on Body Weight of Naltrexone/Bupropion in Overweight and Obese Participants with Cardiovascular Risk Factors in a Large Randomized Double-Blind Study

Halseth, A. E., Shan, K., Gilder, K. M., & Buse, J. B. (2017) · World Academy of Science, Engineering and Technology, International Journal of Medical and Health Sciences · Cited by 1 · see citing works

Efficacy and safety of a short-time orlistat treatment in obese subjects

Gentile, S., Guarino, G., Padovano, B., Buonocunto, F., Annunziata, S., Armentano, V., Corigliano, G., Matteo, A. D., Riu, S. D., Fierro, M. J. C. G., et al. (2005) · Cited by 1 · see citing works

IMPROVEMENT IN IWQOL-LITE-DERIVED HEALTH UTILITY SCORE WITH LIRAGLUTIDE 3.0 MG VERSUS PLACEBO OVER 3 YEARS IN PREDIABETES

Kolotkin, R. L., Smolarz, B. G., Meincke, H. H., & Bjorner, J. B. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.1000 · Cited by 1 · see citing works

The effect of liraglutide 3.0 mg for weight management on HRQoL, as measured by SF-36: 3-year data

Bjørner, J. B., Brett, J., Meincke, H. H., & Kolotkin, R. L. (2016) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 1 · see citing works

Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

McGowan, B. M., Fujioka, K., Greenway, F. L., Krempf, M., le Roux, C. W., Vettor, R., Lilleøre, S. K., & Astrup, A. V. (2017) · Endocrine Abstracts · doi:10.1530/endoabs.48.p1 · Cited by 1 · see citing works

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)

Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473 · see citing works

2024 ESC Guidelines for the management of elevated blood pressure and hypertension

McEvoy, J. W., McCarthy, C. P., Bruno, R. M., Brouwers, S., Canavan, M. D., Ceconi, C., Christodorescu, R. M., Daskalopoulou, S. S., Ferro, C. J., Gerdts, E., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae178 · Cited by 2,298 · see citing works

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association

Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works

Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery

Shariq, O. A., & McKenzie, T. J. (2020) · Gland Surgery · doi:10.21037/gs.2019.12.03 · Cited by 396 · see citing works

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 386 · see citing works

Medications for Obesity: A Review

Gudzune, K. A., & Kushner, R. F. (2024) · JAMA · doi:10.1001/jama.2024.10816 · Cited by 263 · see citing works

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 295 · see citing works

American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease – 2025 Update

Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141 · see citing works

Cyanidin‐3‐glucoside increases whole body energy metabolism by upregulating brown adipose tissue mitochondrial function

You, Y., Yuan, X., Liu, X., Chen, L., Meng, M., Huang, Y., Han, X., Guo, J., Guo, Y. M., Ren, C., et al. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700261 · Cited by 91 · see citing works

Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐Analysis

Lei, X., Ruan, J., Lai, C., Sun, Z., & Yang, X. (2021) · Obesity · doi:10.1002/oby.23152 · Cited by 75 · see citing works

Effectiveness and safety of drugs for obesity

Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66 · see citing works

Clinical practice guideline for the management of hypertension in China

Chinese Society of Cardiology, C. M. A., Hypertension Committee of Cross-Straits Medicine Exchange Association, & Cardiovascular Disease Prevention and Rehabilitation Committee, C. A. O. R. M. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003431 · Cited by 62 · see citing works

Effect of weight loss on blood pressure changes in overweight patients: A systematic review and meta‐analysis

Yang, S., Zhou, Z., Miao, H., & Zhang, Y. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14661 · Cited by 55 · see citing works

The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis

Kennedy, C., Hayes, P. C., Salama, S., Hennessy, M., & Fogacci, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030772 · Cited by 51 · see citing works

The Role of Medicinal and Aromatic Plants against Obesity and Arthritis: A Review

Paul, A. K., Jahan, R., Paul, A., Mahboob, T., Bondhon, T. A., Jannat, K., Hasan, A., Nissapatorn, V., Wilairatana, P., Pereira, M. D. L., et al. (2022) · Nutrients · doi:10.3390/nu14050985 · Cited by 50 · see citing works

Identification of pancreatic lipase inhibitors from Eucommia ulmoides tea by affinity-ultrafiltration combined UPLC-Orbitrap MS and in vitro validation

Huang, H. F., Han, M.-H., Gu, Q., Wang, J., Zhao, H., Zhai, B.-W., Nie, S., Liu, Z., & Fu, Y.-J. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.136630 · Cited by 46 · see citing works

Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis

Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 46 · see citing works

2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America

Sanchez, R. A., Coca, A., Molina, D. I., Alcocer, L. A., Aristizábal, D., Barbosa, E. C. D., Brandão, A. A., Diaz-Velazco, M. E., Hernández-Hernández, R., López-Jaramillo, P. A., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003899 · Cited by 32 · see citing works

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 29 · see citing works

Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes

Jee, W., Lee, S.-H., Ko, H. M., Jung, J. H., Chung, W., & Jang, H.-J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910405 · Cited by 23 · see citing works

Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)

Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 23 · see citing works

Sulfated Glucan from the Green Seaweed Caulerpa sertularioides Inhibits Adipogenesis through Suppression of Adipogenic and Lipogenic Key Factors

Filho, G. P. C., Batista, L. A. N. C., de Medeiros, S., Rocha, H. A. O., & Moreira, S. M. G. (2022) · Marine Drugs · doi:10.3390/md20080470 · Cited by 20 · see citing works

Lifestyle modifications and non-pharmacological management in elderly hypertension

Tsai, H., Chuang, H., Liao, W.-H., Wang, Y.-J., Li, P., Wang, W., Liao, S., Yeh, C., Chen, P., Lai, T., et al. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.10.022 · Cited by 35 · see citing works

Sibutramine as a Cause of Sudden Cardiac Death

Guerra, M. A. R., Yadav, M., Bhandari, M., Sinha, A., Bella, J. N., & Sklyar, E. (2021) · Case Reports in Cardiology · doi:10.1155/2021/8896932 · Cited by 19 · see citing works

Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules

Song, H., Ma, H., Shi, J., Liu, Y., Kan, C., Hou, N., Han, J. D. J., Sun, X., & Qiu, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125148 · Cited by 18 · see citing works

Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis

Shah, R. H., Vedantam, S., Kumar, S., Amin, S., Pearlman, M. Y., & Bhalla, S. (2023) · Obesity Surgery · doi:10.1007/s11695-022-06437-7 · Cited by 17 · see citing works

Obesity and its management in primary care setting

Ibrahim, M. A., Ba-Essa, E. M., Alvarez, J. A., Baker, J. C., Bruni, V., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Domenico, F. D., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109045 · Cited by 17 · see citing works

Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity

Barrea, L., Boschetti, M., Gangitano, E., Guglielmi, V., Verde, L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00602-y · Cited by 16 · see citing works

Freeze-dried biotics based on Lactiplantibacillus plantarum and Lactiplantibacillus paraplantarum with enhanced selected biological activity

Păcularu‐Burada, B., Grigore‐Gurgu, L., Cotârleț, M., Vasile, A. M., Nistor, O. V., Cîrciumaru, A., Gabriela Râpeanu, B., Bahrim, G. E., & Stănciuc, N. (2024) · LWT · doi:10.1016/j.lwt.2024.116339 · Cited by 15 · see citing works

Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments

Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 17 · see citing works

Compliance to Multidisciplinary Lifestyle Intervention Decreases Blood Pressure in Patients with Resistant Hypertension: A Cross-Sectional Pilot Study

Espinel, E., Azancot, M. A., Gómez, A., Beneria, A., Caraben, A., Andurell, L., Delgado, P., Castañé, H., Joven, J., & Serón, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020679 · Cited by 15 · see citing works

What is the evidence regarding the safety of new obesity pharmacotherapies

Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15 · see citing works

Pharmacotherapy of obesity in complex diseases

Pulipati, V. P., & Pannain, S. (2021) · Clinical Obesity · doi:10.1111/cob.12497 · Cited by 13 · see citing works

Achievement rate of target blood pressure in patients with hypertension treated by hypertension specialists and non-specialists in a real-world setting

Sakima, A., Yamazato, M., Kohagura, K., Ishida, A., Matayoshi, T., Tana, T., Nakamura, Y., & Ohya, Y. (2023) · Hypertension Research · doi:10.1038/s41440-023-01362-3 · Cited by 12 · see citing works

Decoding the anti-hypertensive mechanism of α-mangostin based on network pharmacology, molecular docking and experimental validation

Xue, Q.-Q., Liu, C., & Li, Y. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01001-8 · Cited by 12 · see citing works

EFEITOS RELACIONADOS AO USO DE SIBUTRAMINA: UMA REVISÃO DE LITERATURA INTEGRATIVA

Guimarães, A. C. C., Nunes, G. C. O., Alves, I. P. F., Bergamini, P. L. L., & de Oliveira, D. (2022) · Revista Gestão e Conhecimento · doi:10.55908/rgcv16n3-005 · Cited by 11 · see citing works

Nipsnap1—A regulatory factor required for long-term maintenance of non-shivering thermogenesis

Liu, Y., Qu, Y., Cheng, C., Tsai, P.-Y., Edwards, K., Xue, S., Pandit, S., Eguchi, S., Sanghera, N., & Barrow, J. J. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101770 · Cited by 8 · see citing works

“Anti-obesity medications” or “medications to treat obesity” instead of “weight loss drugs” – why language matters – an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM)

Halpern, B., Mancini, M. C., van de Sande‐Lee, S., & Miranda, P. A. C. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0174 · Cited by 8 · see citing works

A review on drug repurposing applicable to obesity

Chen, F., Jing, K., Zhang, Z., & Liu, X. (2024) · Obesity Reviews · doi:10.1111/obr.13848 · Cited by 7 · see citing works

Cardiovascular effects of anti-obesity medications: the perils and promise

Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7 · see citing works

Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension

Barillas-Lara, M. I., Faaborg-Andersen, C. C., Quintana, R. A., Loro-Ferrer, J. F., Mandras, S. A., & daSilva‐deAbreu, A. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001069 · Cited by 5 · see citing works

Pharmacological Advances to the Treatment of Obesity

Londoño-Lemos, M. E. (2018) · Journal of Childhood Obesity · doi:10.21767/2572-5394.100043 · Cited by 5 · see citing works

Evaluation of Pharmacologic Interventions for Weight Management in a Veteran Population

Hood, S. (2021) · Federal Practitioner · doi:10.12788/fp.0117 · Cited by 4 · see citing works

Association between “Life's Essential 8” cardiovascular health and apparent treatment-resistant hypertension among US adults from the NHANES, 2005 to 2018

Xu, Z.-J., Shen, R.-M., Hu, W., Shen, J., Wu, X., & Lv, L. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1453563 · Cited by 3 · see citing works

Current options in obesity pharmacotherapy for children and adolescents

Jung, H. W. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00093 · Cited by 3 · see citing works

Antidiabetic and Hypolipidemic Properties of Newly Isolated Wild Lacticaseibacillus paracasei Strains in Mature Adipocytes

Григорова, Н., Ivanova, Z., Vachkova, Е., Petrova, V., & Beev, G. (2023) · Applied Sciences · doi:10.3390/app13116489 · Cited by 3 · see citing works

Large area fractional laser treatment of mouse skin increases energy expenditure

Salma, N., Evers, M., Karasik, D., Yerevanian, A. I., Downs, H., Luo, T., Doyle, A. E., Tannous, Z. S., Cacicedo, J. M., & Manstein, D. (2023) · iScience · doi:10.1016/j.isci.2023.108677 · Cited by 4 · see citing works

A review on the current drugs and new targets for obesity

Poojashree, M. J. (2020) · Journal of Applied Pharmaceutical Research · doi:10.18231/j.joapr.2019.v.8.i.1.002 · Cited by 3 · see citing works

Current trends in the use of anticonvulsants in psychiatric practice

Demyanov, I. A., Surikova, V. V., & Melnik, E. Y. (2017) · Vestnik of Saint Petersburg University Medicine · doi:10.21638/11701/spbu11.2017.303 · Cited by 3 · see citing works

Polyphenols From Mallotus peltatus (Geiseler) Mull. Arg. Ameliorates FFA‐Induced Hepatic Steatosis in L02 Cells and Reduces Lipid Accumulation in Caenorhabditis elegans

Hao, K., Zhang, Y., Li, Y., Zhong, R., Wang, X., Chang, X. M., Jiang, J., & Zhu, W. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400689 · Cited by 2 · see citing works

Interdisziplinäre S3-Leitlinie zur „Prävention und Therapie der Adipositas“ der Deutschen Adipositas-Gesellschaft (DAG) – Überblick über die Empfehlungen zu den Themen „Stigmatisierung“, „Diagnostik“ und „Therapie“

de Zwaan, M., Hauner, H., Holzapfel, C., Engeli, S., Leitlinienkoordinator*in, S. F. A. A., & Adipositas):, V. D. K. T. (. D. Z. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2552-3990 · Cited by 2 · see citing works

Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists

Grenet, G., Gougeon, A., Salzwedel, D. M., Jauca, C. D., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016144 · Cited by 1 · see citing works

Prevention and intervention against obesity and overweight in the military: a systematic review

Scheit, L., Baustert, L., & Schroeder, J. (2025) · Journal of occupational medicine and toxicology · doi:10.1186/s12995-025-00480-7 · Cited by 1 · see citing works

Revisão da literatura sobre as principais drogas vigentes para tratamento da obesidade no Brasil

PIZZOL, M. H., Gerônimo, R. M. P., Pereira, G. L., Rodrigues, A. G., AMARAL, F. H. F. D., Neto, C. M. G., Oliveira, T. M. D., CECCON, R., Silva, S. O., Guimarães, B. B. S., et al. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n4-153 · Cited by 1 · see citing works

The Therapeutic Aspects of Obesity

Bentsa, T. М. (2023) · Family medicine European practices · doi:10.30841/2786-720x.3.2023.289357 · Cited by 1 · see citing works

The effects of antiseizure medications on comorbidities

Rugg‐Gunn, F. J., & Patsalos, P. N. (2024) · doi:10.1093/med/9780198820758.003.0003 · Cited by 1 · see citing works

Faculty Opinions recommendation of Resistant hypertension: detection, evaluation, and management: A scientific statement from the american heart association.

Manolis, A. J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734299250.793571584 · Cited by 1 · see citing works

Nutrients Intake and Hypertension

Fantin, F. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-663-8

For adults with obesity and hypertension, what are the long-term effects of orlistat or naltrexone/bupropion?

Ho, M. (2021) · Cochrane Clinical Answers · doi:10.1002/cca.3552

Multidisciplinary Lifestyle Interventions In The Management of Resistant HypertensionPreprint

Espinel, E., Azancot, M. A., Gómez, A., Beneria, A., Caraben, A., Andurell, L., Delgado, P., Castañé, H., Joven, J., & Serón, D. (2022) · Research Square · doi:10.21203/rs.3.rs-1279430/v1

AÇÃO DOS ISGLT2 NO HIPERTENSO DIABÉTICO, QUANDO INDICAR?

Bianco, H. T. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212804283-7

Pharmacotherapy for adults with overweight and obesity

Sturgiss, E. A., Ball, L., Blane, D., Hennessy, M., & Quigley, F. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00787-5

Letter to the Editor: Off-label drugs for obesity

Morgan, A., Sturgiss, E. A., & Proietto, J. (2022) · Australian Prescriber · doi:10.18773/austprescr.2022.046

The pharmacological treatment of obesity: A historical perspective

Cuenca-Ecuador., U. C. D. C., Pacheco, A. V. G., Peláez, C. E. A., & Ortíz, R. (2022) · Gaceta Médica de Caracas · doi:10.47307/gmc.2022.130.s3.27

Abordagens personalizadas no tratamento da hipertensão arterial: otimização da terapia farmacológica com base em fatores individuais

Araujo, B. C. V., dos Santos, J. V. R., Duarte, J. B., Abreu, E. T., & Rassilan, F. D. C. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n2-463

Randomized Controlled Trial of a Digital Therapeutics System for Treating New-onset Mild Hypertension (Preprint)Preprint

Deng, Y., Wang, S., Liu, L., He, X., Wang, J., & Yan, J. H. (2024) · doi:10.2196/preprints.64322

Hypertonie

Engeli, S., May, M., & Jordan, J. (2024) · Springer eBooks · doi:10.1007/978-3-662-58895-6_22

Рекомендації Європейського товариства кардіологів ESC 2024 з лікування підвищеного артеріального тиску та гіпертензії

McEvoy, J. W., McCarthy, C. P., Brouwers, S., & Others, A. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.372 · Cited by 1 · see citing works

Long-term effects of weight-reducing drugs in people with hypertension

Spary-Kainz, U., Posch, N. A. S., Radl-Karimi, C., Jeitler, K., Krenn, C., Siebenhofer, A., Berghold, A., Horvath, K., Winterholer, S., & Semlitsch, T. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub6

Oral Agents Used to Treat Type 2 Diabetes and Obesity

Liddle, J., Ratkova, E. L., Bonito, C. A., Rhodes, C. J., & Will, S. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch5

Long-term effects of weight-reducing drugs in hypertensive patients

Siebenhofer, A., Jeitler, K., Horvath, K., Berghold, A., Siering, U., & Semlitsch, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub3 · Cited by 51 · see citing works

D66 Should weight loss drugs be used to treat or prevent hypertension?

Cooper, R. (1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)89095-4

Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients Systematic Review and Meta-analysis

Horvath, K. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.6.571 · Cited by 141 · see citing works

Long-term effects of weight-reducing diets in people with hypertension

Semlitsch, T., Jeitler, K., Berghold, A., Horvath, K., Posch, N., Poggenburg, S., & Siebenhofer, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008274.pub3 · Cited by 118 · see citing works

Choice of drug treatment for obesity-related hypertension: where is the evidence?

Sharma, A. M., Pischon, T., Engeli, S., & Scholze, J. E. (2001) · Journal of Hypertension · doi:10.1097/00004872-200104000-00001 · Cited by 91 · see citing works